{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:45:51Z","timestamp":1786715151875,"version":"build-2736575974"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian J Pharmacol"],"published-print":{"date-parts":[[2016]]},"DOI":"10.4103\/0253-7613.190764","type":"journal-article","created":{"date-parts":[[2016,9,19]],"date-time":"2016-09-19T08:18:14Z","timestamp":1474273094000},"page":"601","source":"Crossref","is-referenced-by-count":12,"title":["Isotretinoin-induced acute severe myopathy involving pelvic girdle muscles: A case report"],"prefix":"10.4103","volume":"48","author":[{"family":"Semira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Sameem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0253-7613.190764-1","first-page":"1816","volume-title":"Oral isotretinoin as the most effective treatment in folliculitis decalvans: A retrospective comparison of different treatment regimens in 28 patients","author":"Tietze","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/0253-7613.190764-2","first-page":"360","volume-title":"Long-term safety of isotretinoin as a treatment for acne vulgaris","author":"Goulden","year":"1994","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/0253-7613.190764-3","first-page":"213","volume-title":"Drug-related myopathies of which the clinician should be aware","author":"Valiyil","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"key-10.4103\/0253-7613.190764-4","doi-asserted-by":"crossref","unstructured":"Ganceviciene R, Zouboulis CC. Isotretinoin: State of the art treatment for acne vulgaris. Expert Rev Dermatol 2007;2:693-701.","DOI":"10.1586\/17469872.2.6.693"},{"key":"key-10.4103\/0253-7613.190764-5","first-page":"398","volume-title":"Creatine phosphokinase values during isotretinoin treatment for acne","author":"Kaymak","year":"2008","journal-title":"Int J Dermatol"},{"key":"key-10.4103\/0253-7613.190764-6","first-page":"94","volume-title":"Muscular damage during isotretinoin treatment","author":"Heudes","year":"1998","journal-title":"Ann Dermatol Venereol"},{"key":"key-10.4103\/0253-7613.190764-7","first-page":"25","volume-title":"Neuromuscular adverse effects associated with systemic retinoid dermatotherapy: Monitoring and treatment algorithm for clinicians","author":"Chroni","year":"2010","journal-title":"Drug Saf"},{"key":"key-10.4103\/0253-7613.190764-8","first-page":"141","volume-title":"Isotretinoin and FoxO1: A scientific hypothesis","author":"Melnik","year":"2011","journal-title":"Dermatoendocrinol"},{"key":"key-10.4103\/0253-7613.190764-9","first-page":"395","volume-title":"The IGF-1\/PI3K\/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors","author":"Stitt","year":"2004","journal-title":"Mol Cell"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:25:41Z","timestamp":1786713941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0253-7613.190764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"alternative-id":["190764"],"URL":"https:\/\/doi.org\/10.4103\/0253-7613.190764","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}